Free Submission Public Relations & NewsPR-inside.com
 
DeutschEnglish

Get the latest news
with our RSS feed
rss feed
Add to My Yahoo!
More information
Business

ArQule and Daiichi-Sankyo Enter Into Strategic R&D Partnership to Progress Novel Compounds to Target Cancer


Print article Print article
Refer this article Refer to a friend
© Business Wire 2008
2008-11-10 13:05:00 -

www.arqule.com - ArQule, Inc. William B. Boni, 781-994-0300 VP, Investor Relations/ Corp. Communications www.ArQule.com or Daiichi Sankyo (Tokyo) Toshiaki Sai, + 81-3-6225-1126 or Daiichi Sankyo, Inc. (USA) Richard Salem, 973-695-8330

Product development agreement focused on ARQ 197, c-Met inhibitor,
with discovery collaboration directed toward novel kinase inhibitors;
Total cash upfront to ArQule is $75 million;

ArQule's conference call scheduled today (November 10) at 9:00 AM
eastern time


Disclaimer: (c) 2009 Business Wire. All of the news releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Terms & Conditions | Privacy | About us | Contact PR-inside.com